Legal Representation
Attorney
Austin Padgett
USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 9, 2018 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Oct 8, 2018 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Feb 22, 2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 20, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 20, 2018 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 20, 2018 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Sep 5, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 23, 2017 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| May 1, 2017 | CHPB | I | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED | Loading... |
| Apr 25, 2017 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Apr 21, 2017 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Mar 30, 2017 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Mar 14, 2017 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 14, 2017 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 22, 2017 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 2, 2017 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 27, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 25, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 22, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions; all excluding pharmaceutical preparations and medicines administered via inhaler and pharmaceutical preparations and medicines for respiratory therapy or the treatment of respiratory diseases and disorders
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005